Predictive Value of Corrected 18F-FDG PET/CT Baseline Parameters for Primary DLBCL Prognosis: A Single-center Study
Authors:
Open Access
- 13 February 2024
- journal article
- research article
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 23 (01) , 033-042
Abstract
Objective The purpose of this study was to evaluate the prognostic significance of corrected baseline metabolic parameters in fluorodeoxyglucose positron emission tomography imaging (18F-FDG PET/CT) for 3-year progression-free survival (PFS) in patients with primary diffuse large B cell lymphoma (DLBCL). Patients and Methods Retrospective clinical and pathological data were collected for 199 patients of DLBCL diagnosed between January 2018 and January 2021. All patients underwent 18F-FDG PET/CT scans without any form of treatment. The corrected maximum standardized uptake value (corSUVmax), corrected mean standardized uptake value (corSUVmean), corrected whole-body tumor metabolic volume sum (corMTVsum), and corrected total lesion glycolysis of whole body (corTLGtotal) were corrected using the SUVmean in a 1-cm diameter mediastinal blood pool (MBP) from the descending thoracic aorta of patients. Kaplan–Meier survival curves and Cox regression were used to examine the predictive significance of corrected baseline metabolic parameters on 3-year PFS of patients. The incremental values of corrected baseline metabolic parameters were evaluated by using Harrell's C-indices, receiver operating characteristic, and Decision Curve Analysis. Results The multivariate analysis revealed that only the National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and corMTVsum had an effect on 3-year PFS of patients (p < 0.05, respectively). The Kaplan–Meier survival analysis demonstrated significant differences in PFS between the risk groups classified by corSUVsum, corMTVsum, and corTLGtotal (log-rank test, p < 0.05). The predictive model composed of corMTVsum and corTLGtotal surpasses the predictive performance of the model incorporating MTVsum and TLGtotal. The optimal performance was observed when corMTVsum was combined with NCCN-IPI, resulting in a Harrell's C index of 0.785 and area under the curve values of 0.863, 0.891, and 0.947 for the 1-, 2-, and 3-year PFS rates, respectively. Conclusion The corMTVsum offers significant prognostic value for patients with DLBCL. Furthermore, the combination of corMTVsum with the NCCN-IPI can provide an accurate prediction of the prognosis. * These authors contributed equally to this work and retain the first authorship. Article published online: 13 February 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, IndiaKeywords
This publication has 30 references indexed in Scilit:
- F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphomaEuropean Journal of Haematology, 2014
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraBlood, 2014
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphomaBlood, 2013
- Relapsed/Refractory Diffuse Large B-Cell LymphomaHematology-American Society Hematology Education Program, 2011
- Improving Outcomes for Patients With Diffuse Large B-Cell LymphomaCA: A Cancer Journal for Clinicians, 2010
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Partial volume correction strategies for quantitative FDG PET in oncologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993